tetano
Editor, Senior Moderator
Science
. 2020 Jun 15;eabc7424.
doi: 10.1126/science.abc7424. Online ahead of print.
Broad Neutralization of SARS-related Viruses by Human Monoclonal Antibodies
Anna Z Wec[SUP] 1 [/SUP], Daniel Wrapp[SUP] 2 [/SUP], Andrew S Herbert[SUP] 3 [/SUP], Daniel P Maurer[SUP] 1 [/SUP], Denise Haslwanter[SUP] 4 [/SUP], Mrunal Sakharkar[SUP] 1 [/SUP], Rohit K Jangra[SUP] 4 [/SUP], M Eugenia Dieterle[SUP] 4 [/SUP], Asparouh Lilov[SUP] 1 [/SUP], Deli Huang[SUP] 5 [/SUP], Longping V Tse[SUP] 6 [/SUP], Nicole V Johnson[SUP] 2 [/SUP], Ching-Lin Hsieh[SUP] 2 [/SUP], Nianshuang Wang[SUP] 2 [/SUP], Juergen H Nett[SUP] 1 [/SUP], Elizabeth Champney[SUP] 1 [/SUP], Irina Burnina[SUP] 1 [/SUP], Michael Brown[SUP] 1 [/SUP], Shu Lin[SUP] 1 [/SUP], Melanie Sinclair[SUP] 1 [/SUP], Carl Johnson[SUP] 1 [/SUP], Sarat Pudi[SUP] 1 [/SUP], Robert Bortz 3rd[SUP] 4 [/SUP], Ariel S Wirchnianski[SUP] 4 [/SUP], Ethan Laudermilch[SUP] 4 [/SUP], Catalina Florez[SUP] 4 [/SUP], J Maximilian Fels[SUP] 4 [/SUP], Cecilia M O'Brien[SUP] 3 [/SUP], Barney S Graham[SUP] 7 [/SUP], David Nemazee[SUP] 5 [/SUP], Dennis R Burton[SUP] 5 8 9 10 [/SUP], Ralph S Baric[SUP] 6 11 [/SUP], James E Voss[SUP] 5 [/SUP], Kartik Chandran[SUP] 4 [/SUP], John M Dye[SUP] 3 [/SUP], Jason S McLellan[SUP] 2 [/SUP], Laura M Walker[SUP] 12 [/SUP]
Affiliations
Abstract
Broadly protective vaccines against known and pre-emergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of pre-existing memory B cells (MBCs) elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines.
. 2020 Jun 15;eabc7424.
doi: 10.1126/science.abc7424. Online ahead of print.
Broad Neutralization of SARS-related Viruses by Human Monoclonal Antibodies
Anna Z Wec[SUP] 1 [/SUP], Daniel Wrapp[SUP] 2 [/SUP], Andrew S Herbert[SUP] 3 [/SUP], Daniel P Maurer[SUP] 1 [/SUP], Denise Haslwanter[SUP] 4 [/SUP], Mrunal Sakharkar[SUP] 1 [/SUP], Rohit K Jangra[SUP] 4 [/SUP], M Eugenia Dieterle[SUP] 4 [/SUP], Asparouh Lilov[SUP] 1 [/SUP], Deli Huang[SUP] 5 [/SUP], Longping V Tse[SUP] 6 [/SUP], Nicole V Johnson[SUP] 2 [/SUP], Ching-Lin Hsieh[SUP] 2 [/SUP], Nianshuang Wang[SUP] 2 [/SUP], Juergen H Nett[SUP] 1 [/SUP], Elizabeth Champney[SUP] 1 [/SUP], Irina Burnina[SUP] 1 [/SUP], Michael Brown[SUP] 1 [/SUP], Shu Lin[SUP] 1 [/SUP], Melanie Sinclair[SUP] 1 [/SUP], Carl Johnson[SUP] 1 [/SUP], Sarat Pudi[SUP] 1 [/SUP], Robert Bortz 3rd[SUP] 4 [/SUP], Ariel S Wirchnianski[SUP] 4 [/SUP], Ethan Laudermilch[SUP] 4 [/SUP], Catalina Florez[SUP] 4 [/SUP], J Maximilian Fels[SUP] 4 [/SUP], Cecilia M O'Brien[SUP] 3 [/SUP], Barney S Graham[SUP] 7 [/SUP], David Nemazee[SUP] 5 [/SUP], Dennis R Burton[SUP] 5 8 9 10 [/SUP], Ralph S Baric[SUP] 6 11 [/SUP], James E Voss[SUP] 5 [/SUP], Kartik Chandran[SUP] 4 [/SUP], John M Dye[SUP] 3 [/SUP], Jason S McLellan[SUP] 2 [/SUP], Laura M Walker[SUP] 12 [/SUP]
Affiliations
- PMID: 32540900
- DOI: 10.1126/science.abc7424
Abstract
Broadly protective vaccines against known and pre-emergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of pre-existing memory B cells (MBCs) elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines.